Europe Ophthalmic Drugs Market Forecast 2023-2032

The Europe ophthalmic drugs market is expected to register a CAGR of 5.70% during the forecast period, 2023-2032. European pharmaceutical firms make substantial investments in research and development to create innovative ophthalmic drugs and therapies, aimed at meeting unfulfilled medical requirements and broadening the market.

MARKET INSIGHTS

Belgium, Spain, Poland, Italy, the United Kingdom, France, Germany, and Rest of Europe are assessed for the Europe ophthalmic drugs market growth analysis. The German ophthalmic drugs market plays a crucial role in the nation's healthcare sector, spurred by various factors. A key driver is the increasing prevalence of eye disorders, primarily attributed to the aging population. Germany, akin to many developed nations, is experiencing a rise in age-related eye conditions such as cataracts and age-related macular degeneration, necessitating the utilization of ophthalmic drugs for treatment and management.

Another contributing factor to the German ophthalmic drugs market is the progress in drug therapies and delivery methods. These advancements have resulted in more effective and patient-friendly treatment options for eye disorders. In Germany, patients benefit from state-of-the-art drug delivery technologies, fueling the growing demand for ophthalmic drugs.

Despite these favorable aspects, the market encounters challenges. Stringent regulatory approval processes, crucial for ensuring patient safety, can lead to delays in introducing new ophthalmic medications to the market. This robust regulatory environment aims to guarantee the safety and efficacy of these drugs, upholding high standards of patient care.

COMPETITIVE INSIGHTS

Novartis AG, Thea Pharma Inc, Pfizer Inc, etc., are among the leading companies in the market.

Our report offerings include:

Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation caters to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 74012

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
- 2.4.1. IMPACT OF COVID-19 ON OPHTHALMIC DRUGS MARKET
2.5. MAJOR MARKET FINDINGS
- 2.5.1. EMERGING THERAPIES FOR DRY EYE SYNDROME
- 2.5.2. GROWING DEMAND FOR COMBINATION THERAPIES
- 2.5.3. INCREASING INVESTMENT IN RESEARCH & DEVELOPMENT
- 2.5.4. SHIFT TOWARD OVER-THE-COUNTER (OTC) PRODUCTS

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. AGING POPULATION'S SUSCEPTIBILITY TO AGE-RELATED EYE CONDITIONS
- 3.1.2. ADVANCEMENTS IN DRUG DELIVERY TECHNOLOGIES
- 3.1.3. RISING PREVALENCE OF EYE DISEASES AND DISORDERS
- 3.1.4. FAVORABLE REIMBURSEMENT POLICIES BY HEALTHCARE SYSTEMS
3.2. KEY RESTRAINTS
- 3.2.1. DELAY IN DRUG APPROVALS
- 3.2.2. SIDE EFFECTS RELATED TO OPHTHALMIC DRUGS

4. KEY ANALYTICS

4.1. KEY MARKET TRENDS
4.2. TECHNOLOGY SNAPSHOT
- 4.2.1. BIOLOGICS
- 4.2.2. CELL THERAPY
- 4.2.3. GENE THERAPY
- 4.2.4. DRUG DELIVERY
- 4.2.5. SMALL MOLECULE
- 4.2.6. OTHER TECHNOLOGIES
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. KEY BUYING CRITERIA
4.8. REGULATORY FRAMEWORK

5. MARKET BY INDICATION

5.1. DRY EYE
5.2. GLAUCOMA
5.3. INFECTION/INFLAMMATION/ALLERGIES
5.4. RETINAL DISORDER
- 5.4.1. WET AGE-RELATED MACULAR DEGENERATION
- 5.4.2. DRY AGE-RELATED MACULAR DEGENERATION
- 5.4.3. DIABETIC RETINOPATHY
- 5.4.4. OTHER RETINAL DISORDERS
5.5. OTHER INDICATIONS

6. MARKET BY TYPE

6.1. PRESCRIPTION DRUGS
6.2. OVER-THE-COUNTER DRUGS

7. MARKET BY DOSAGE FORM

7.1. GELS
7.2. EYE SOLUTIONS & SUSPENSIONS
7.3. CAPSULES & TABLETS
7.4. EYE DROPS
7.5. OINTMENTS

8. MARKET BY THERAPEUTIC CLASS

8.1. ANTI-GLAUCOMA
8.2. ANTI-INFECTION
8.3. ANTI-INFLAMMATORY
8.4. ANTI-ALLERGY
8.5. OTHER THERAPEUTIC CLASSES

9. MARKET BY DISTRIBUTION CHANNEL

9.1. HOSPITAL PHARMACIES
9.2. DRUG STORES
9.3. ONLINE PHARMACIES
9.4. OTHER DISTRIBUTION CHANNELS

10. GEOGRAPHICAL ANALYSIS

10.1. EUROPE
- 10.1.1. MARKET SIZE & ESTIMATES
- 10.1.2. EUROPE OPHTHALMIC DRUGS MARKET DRIVERS
- 10.1.3. EUROPE OPHTHALMIC DRUGS MARKET CHALLENGES
- 10.1.4. KEY PLAYERS IN EUROPE OPHTHALMIC DRUGS MARKET
- 10.1.5. COUNTRY ANALYSIS
  - 10.1.5.1. UNITED KINGDOM
  - 10.1.5.1.1. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.1.5.2. GERMANY
  - 10.1.5.2.1. GERMANY OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.1.5.3. FRANCE
  - 10.1.5.3.1. FRANCE OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.1.5.4. ITALY
  - 10.1.5.4.1. ITALY OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.1.5.5. SPAIN
  - 10.1.5.5.1. SPAIN OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.1.5.6. BELGIUM
  - 10.1.5.6.1. BELGIUM OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.1.5.7. POLAND
  - 10.1.5.7.1. POLAND OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.1.5.8. REST OF EUROPE
  - 10.1.5.8.1. REST OF EUROPE OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES

11. COMPETITIVE LANDSCAPE

11.1. KEY STRATEGIC DEVELOPMENTS
- 11.1.1. MERGERS & ACQUISITIONS
- 11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 11.1.3. PARTNERSHIPS & AGREEMENTS
11.2. COMPANY PROFILES
- 11.2.1. ABBVIE INC
  - 11.2.1.1. COMPANY OVERVIEW
  - 11.2.1.2. PRODUCTS & SERVICES
  - 11.2.1.3. STRENGTHS & CHALLENGES
- 11.2.2. ACCUTOME INC
  - 11.2.2.1. COMPANY OVERVIEW
  - 11.2.2.2. PRODUCTS & SERVICES
  - 11.2.2.3. STRENGTHS & CHALLENGES
- 11.2.3. BAUSCH HEALTH COMPANIES INC
  - 11.2.3.1. COMPANY OVERVIEW
  - 11.2.3.2. PRODUCTS & SERVICES
  - 11.2.3.3. STRENGTHS & CHALLENGES
- 11.2.4. GENENTECH INC
  - 11.2.4.1. COMPANY OVERVIEW
  - 11.2.4.2. PRODUCTS & SERVICES
  - 11.2.4.3. STRENGTHS & CHALLENGES
- 11.2.5. JOHNSON & JOHNSON
  - 11.2.5.1. COMPANY OVERVIEW
  - 11.2.5.2. PRODUCTS & SERVICES
  - 11.2.5.3. STRENGTHS & CHALLENGES
- 11.2.6. THEA PHARMA INC
  - 11.2.6.1. COMPANY OVERVIEW
  - 11.2.6.2. PRODUCTS & SERVICES
  - 11.2.6.3. STRENGTHS & CHALLENGES
- 11.2.7. NOVARTIS AG
  - 11.2.7.1. COMPANY OVERVIEW
  - 11.2.7.2. PRODUCTS & SERVICES
  - 11.2.7.3. STRENGTHS & CHALLENGES
- 11.2.8. PFIZER INC
  - 11.2.8.1. COMPANY OVERVIEW
  - 11.2.8.2. PRODUCTS & SERVICES
  - 11.2.8.3. STRENGTHS & CHALLENGES
- 11.2.9. REGENERON PHARMACEUTICALS INC
  - 11.2.9.1. COMPANY OVERVIEW
  - 11.2.9.2. PRODUCTS & SERVICES
  - 11.2.9.3. STRENGTHS & CHALLENGES
- 11.2.10. SANTEN PHARMACEUTICAL CO LTD
  - 11.2.10.1. COMPANY OVERVIEW
  - 11.2.10.2. PRODUCTS & SERVICES
  - 11.2.10.3. STRENGTHS & CHALLENGES
- 11.2.11. SUN PHARMACEUTICAL INDUSTRIES LTD
  - 11.2.11.1. COMPANY OVERVIEW
  - 11.2.11.2. PRODUCTS & SERVICES
  - 11.2.11.3. STRENGTHS & CHALLENGES
- 11.2.12. TEVA PHARMACEUTICALS INDUSTRIES LTD
  - 11.2.12.1. COMPANY OVERVIEW
  - 11.2.12.2. PRODUCTS & SERVICES
  - 11.2.12.3. STRENGTHS & CHALLENGES